Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

News

Dr. Reddy’s API team is a 2021 winner in – API Supplier of the year at Global generics & Biosimilars awards

Dr. Reddy’s API team is a 2021 winner in – API Supplier of the year at Global generics & Biosimilars awards

We won the API Supplier of the Year Award for our strong commitment as a reliable API supplier to global formulating companies but also to take on the challenge of being part of the solution to address the pandemic. The nomination reflects on Dr. Reddy’s efforts to bring science, technology, and innovation together to provide a COVID-19 portfolio from prevention (SPUTNIK V) to cure (Remdesivir, Favipiravir, etc..).

At the same time, the team was able to respond to the increased demand for high-quality APIs, which resulted a two-digit growth and helped its partners ensure their medicines are available wherever and whenever needed.

To know more about our API Portfolio, write to us at: api@drreddys.com.

Dr. Reddy’s API team is a 2021 winner in – API Supplier of the year at Global generics & Biosimilars awards

Dr. Reddy’s API team is a 2021 winner in – API Supplier of the year at Global generics & Biosimilars awards

Contact Us

Please fill in the following form and we'll get back to you shortly.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.